Roth Capital Boobalan Pachaiyappan analyst has told investors in a research note that the FDA’s intention not to demand from an advertising “in the deramiical time in its current form. The company reiterates a purchase rating and $ 31 price objective On Capricor actions.
First published The range – The ultimate source of real -time financial and mobile financial on the market. Try now >>
See today’s most efficient actions on Tipranks >>
Learn more about CAPR:
Warning and disclosure
